Ritholtz Wealth Management Decreases Holdings in Sanofi (NASDAQ:SNY)

Ritholtz Wealth Management lowered its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 17.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,559 shares of the company's stock after selling 8,692 shares during the period. Ritholtz Wealth Management's holdings in Sanofi were worth $2,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after buying an additional 33,105 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after acquiring an additional 16,780 shares during the last quarter. GFS Advisors LLC boosted its position in shares of Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after purchasing an additional 11,655 shares during the period. Legacy Capital Wealth Partners LLC increased its holdings in Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company's stock valued at $1,399,000 after purchasing an additional 12,942 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

Sanofi stock remained flat at $50.74 during mid-day trading on Friday. 2,426,236 shares of the company's stock were exchanged, compared to its average volume of 2,173,288. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The firm has a market capitalization of $128.77 billion, a P/E ratio of 25.89, a P/E/G ratio of 1.17 and a beta of 0.57. The stock's fifty day simple moving average is $48.46 and its two-hundred day simple moving average is $52.11.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same period last year, the firm earned $2.55 earnings per share. The company's revenue for the quarter was up 12.3% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 3.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.